Loratadine Sales Keep Perrigo On Track To Meet Core Business Growth Goals
This article was originally published in The Tan Sheet
Executive Summary
Perrigo expects to meet its fiscal 2004 target for core business growth despite continued delays in the approval of its 10 mg loratadine tablets (Schering-Plough's Claritin)